Log In
BCIQ
Print this Print this
 

CM-24

  Manage Alerts
Collapse Summary General Information
Company cCAM Biotherapeutics Ltd.
DescriptionHumanized IgG4 mAb targeting carcinoembryonic antigen (CEA)-related cell adhesion molecule 1 (CEACAM1; CD66a)
Molecular Target Carcinoembryonic antigen (CEA)-related cell adhesion molecule 1 (CEACAM1) (CD66a)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$605.0M

$95.0M

$510.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/31/2015

$605.0M

$95.0M

$510.0M

Get a free BioCentury trial today